Free Newsletter
| Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today! |
Pfizer, Wyeth merger bad idea?
Fortune writer John Simons opines that a rumored merger of Pfizer and Wyeth would be all wrong for both companies. In his view, a merger would amount to a marriage of weaknesses. Pfizer needs blockbusters to overcome looming patent expirations and Wyeth has recently been failing to deliver.
"Would the idea behind the merger be that misery loves company?" says Standard & Poors pharma analyst Herman Saftlas. "Most mergers in this sector haven't panned out from an earnings growth perspective. But even worse, these two companies are in the same boat."
- read Simon's opinion piece
Related Articles:
Wyeth buyout a good deal for Pfizer? Report
What's next for Pfizer? Report
Wyeth stumbles badly trying to develop new drugs. Report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
